Form 4: Terns Pharmaceuticals Director Heather Turner Granted 45,000 Stock Options

Terns Pharmaceuticals, Inc. Director Heather D. Turner was granted 45,000 stock options with an exercise price of $4.10, as disclosed in a recent SEC Form 4 filing.

Summary

• Heather D. Turner, a Director of Terns Pharmaceuticals, Inc. (TERN), was granted 45,000 stock options on June 11, 2025.
• The stock options have an exercise price of $4.10 per share.
• The options will vest in full on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) immediately prior to the Annual Meeting following the grant date.
• The expiration date for these options is June 10, 2035.
• Following this transaction, Heather D. Turner beneficially owns 45,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of options aligns the director's interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The document indicates the future vesting schedule for the granted stock options, which will occur on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date.

Industry Context

This Form 4 filing details a routine equity compensation event for a director, which is a common practice across the biotechnology and pharmaceutical industries to attract and retain talent and align management incentives with shareholder value.

Related Party Transactions

• Heather D. Turner, a Director of Terns Pharmaceuticals, Inc., was granted 45,000 stock options, representing an equity compensation arrangement between the company and a related party.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as positive as it aligns the director's financial incentives with the company's long-term performance and shareholder value creation.

Next Steps

• The stock options will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, Stock Option, Director, Insider Transaction, Equity Compensation, Form 4